America Can Lower Drug Costs Without Sacrificing Medical Innovation
Blindly importing European pricing approaches could pose real risks to future innovation and patient access.
This item is an automated import from an external feed and has not yet been rewritten into a neutral C-IT-ALL summary. Read the full story at the original source below.
Read the full story at National Review
Related Coverage